Business
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value
Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that it has been successfully added as a constituent stock of the Hang Seng Index (HSI) following the release of the Q3 2025 Hang Seng Index Series Quarterly Review results, joining the ranks of blue-chip companies representin
About this update from Global Capital Markets Ltd.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Nov. 23, 2025 /PRNewswire/ -- Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that it has been successfully added as a constituent stock of the Hang Seng Index (HSI) following the release of the Q3 2025 Hang Seng Index Series Quarterly Review results, joining the ranks of blue-chip companies representing Hong Kong's core assets. This milestone makes Innovent the first company that has grown from a biotech into a leading biopharma and been included in the HSI. The company has been concurrently admitted to the Hang Seng China Enterprises Index (HSCEI) and the Hang Seng ESG Enhanced Index. The inclusion in core indices underscores the international capital market's strong recognition of Innovent's value as a leading innovative biopharmaceutical company.","length":1051,"tagName":"p"},{"type":"text","content":"As a flagship indicator of the Hong Kong stock market's performance, the HSI selects constituent stocks based on criteria such as market capitalization, liquidity, industry representation, and financial soundness. Its components comprise the largest and most actively traded leading companies across various sectors in the Hong Kong market, serving as a core reference for global capital allocation in Hong Kong equities.","length":425,"tagName":"p"},{"type":"text","content":"Since its establishment, Innovent has focused on major disease areas including oncology, cardiovascular and metabolism, autoimmune and ophthalmology. Supported by a diversified drug pipeline encompassing monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), small-molecule drugs, etc., Innovent already launched 16 products, and continues to lead in technological innovation and clinical value creation. Meanwhile, Innovent has laid a solid foundation for long-term development by continuously optimizing operational efficiency and financial structure, and earned widespread trust from global investors.","length":628,"tagName":"p"},{"type":"text","content":"Innovent's inclusion in the Hang Seng Index marks that Chinese innovative biopharma companies...